Equities

Pyridam Farma Tbk PT

PYFA:JKT

Pyridam Farma Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)164.00
  • Today's Change10.00 / 6.49%
  • Shares traded229.02m
  • 1 Year change-2.07%
  • Beta1.0909
Data delayed at least 10 minutes, as of Sep 19 2024 10:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of IDR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments89,970136,58047,733
Total Receivables, Net198,463151,755100,991
Total Inventory225,484210,194145,941
Prepaid expenses56,62142,46431,766
Other current assets, total------
Total current assets570,538540,992326,431
Property, plant & equipment, net810,246846,694386,757
Goodwill, net------
Intangibles, net19,11111,17044,830
Long term investments100,082100,59440,240
Note receivable - long term------
Other long term assets3,8894,3561,606
Total assets1,521,2331,520,569806,222
LIABILITIES
Accounts payable62,84668,69495,400
Accrued expenses54,36350,44416,849
Notes payable/short-term debt131,213137,42965,000
Current portion long-term debt/capital leases20,22122,37821,011
Other current liabilities, total25,07218,44453,578
Total current liabilities293,715297,388251,838
Total long term debt835,557750,231362,803
Total debt986,991910,038448,814
Deferred income tax------
Minority interest2262310.51
Other liabilities, total34,90130,59224,480
Total liabilities1,164,3991,078,442639,122
SHAREHOLDERS EQUITY
Common stock53,50853,50853,508
Additional paid-in capital2,0642,0642,065
Retained earnings (accumulated deficit)287,447372,66897,427
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total13,81513,88514,100
Total equity356,834442,126167,100
Total liabilities & shareholders' equity1,521,2331,520,569806,222
Total common shares outstanding2,4922,4922,492
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.